Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0J2VB
|
||||
| Former ID |
DCL000534
|
||||
| Drug Name |
Iboctadekin + rituximab
|
||||
| Drug Type |
Antibody
|
||||
| Indication | Non-hodgkin's lymphoma; Follicular lymphoma [ICD9: 200, 202, 202.0, 202.8; ICD10:C81-C86, C82, C82-C85] | Phase 1 | [549706] | ||
| Company |
GSK
|
||||
| Formula |
C34H63N5O9
|
||||
| Canonical SMILES |
CC(C)CC(C(CC(=O)O)O)NC(=O)C(C)NC(=O)CC(C(CC(C)C)NC(=O)C<br />(C(C)C)NC(=O)C(C(C)C)NC(=O)CC(C)C)O
|
||||
| InChI |
1S/C34H63N5O9/c1-17(2)12-23(37-33(47)31(21(9)10)39-34(48)30(20(7)8)38-27(42)14-19(5)6)25(40)15-28(43)35-22(11)32(46)36-24(13-18(3)4)26(41)16-29(44)45/h17-26,30-31,40-41H,12-16H2,1-11H3,(H,35,43)(H,36,46)(H,37,47)(H,38,42)(H,39,48)(H,44,45)/t22-,23-,24-,25-,26-,30-,31-/m0/s1
|
||||
| InChIKey |
FAXGPCHRFPCXOO-LXTPJMTPSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
584708, 596110, 826106, 829796, 831223, 835624, 7888351, 7979897, 8030793, 11120284, 11120772, 11121260, 11121685, 11122165, 11362754, 11365316, 11367878, 11370779, 11370780, 11373479, 11376040, 11532940, 11693423, 17397905, 22391554, 26681497, 26717873, 26755331, 26755332, 39469856, 46392467, 46393151, 46394382, 46394420, 46488047, 47216569, 47290927, 47662056, 48034869, 48110235, 49683285, 49699079, 50110894, 50110895, 53790185, 57363881, 76985937, 85148375, 85256984, 85261607
|
||||
| Target and Pathway | |||||
| Target(s) | Interleukin-18 | Target Info | Modulator | [550963] | |
| B-lymphocyte antigen CD20 | Target Info | [550963] | |||
| NetPath Pathway | IL4 Signaling Pathway | ||||
| PANTHER Pathway | Interleukin signaling pathway | ||||
| Toll receptor signaling pathway | |||||
| Reactome | Interleukin-1 processing | ||||
| References | |||||